Become Affiliate

PepFlow

Download

The GHRH Fragment

Sermorelin

A 29-amino-acid growth hormone-releasing hormone fragment known as GRF 1-29, used to stimulate pituitary GH release when somatotroph function is intact.

GH pulseRecoverySleep supportHealthy aging
TierB
EvidenceModerate
SafetyModerate Data
FDA statusNot Listed
Last reviewed August 11, 2026 39 citations How to read these labels

What is Sermorelin?

Sermorelin is GHRH(1-29), the shortest N-terminal fragment of growth hormone-releasing hormone that retains GH-releasing activity. It stimulates pituitary GHRH receptors rather than acting through the ghrelin receptor.[14][3]

The 1-29 length matters because the active N-terminal portion of GHRH is enough to stimulate pituitary GH release when somatotroph cells can respond. It is shorter than native GHRH and more route-sensitive than long-acting GHRH analogs.[14][3][29]

Modern use language often places Sermorelin in adult GH-axis support and anti-aging-style contexts, while its core pharmacologic identity remains a pituitary GHRH-receptor signal rather than direct growth hormone replacement.[30][3][24] For more context, read the sermorelin dosage terminology explainer.

What Sermorelin is investigated for

Sermorelin evidence is grouped by practical use case and injectable and intranasal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

GH-axis stimulation

Injectable, Intranasal

66%Moderate

GH-axis stimulation is biologically grounded, but interpretation depends on route, pituitary function, and the population being studied.[14][30]

Human evidence

Human studies support GH response in diagnostic and GH-deficiency contexts.[14][30]

Animal / mechanistic evidence

GHRH(1-29) directly stimulates the pituitary GHRH receptor when somatotroph function is intact.[14][30]

Adult lean-mass and anti-aging support

Injectable

24%Limited

Adult lean-mass, fat-loss, and anti-aging claims should remain cautious, monitored, and distinct from historical GH-deficiency contexts.[4][24]

Human evidence

Adult wellness, lean-mass, fat-loss, and anti-aging outcomes have not been established with large controlled trials.[4][24]

Animal / mechanistic evidence

GHRH physiology supports the idea of upstream GH stimulation.[4][24]

Sleep quality

Injectable

16%Insufficient

Sleep-quality positioning should remain an indirect GH-axis hypothesis, not a demonstrated sermorelin outcome.[4][24]

Human evidence

Dedicated controlled sermorelin sleep-quality endpoint trials are not established.[4][24]

Animal / mechanistic evidence

The sleep rationale is indirect, based on GHRH physiology, nocturnal GH-pulse timing, and adult GH-secretagogue review literature.[14][4]

Anti-aging support

Injectable

12%Insufficient

Anti-aging support is a common reader intent, but it should remain an insufficient-evidence claim separate from GH-axis stimulation.[4][24]

Human evidence

Sermorelin has not shown controlled longevity, healthspan, frailty, or age-reversal outcomes in the cited literature.[4][24]

Animal / mechanistic evidence

The anti-aging rationale is indirect, based on GHRH and GH-axis physiology rather than direct aging biology.[4]

Evidence snapshot

66%

Human evidence

Moderate

GH-response studies, diagnostic use, and pediatric GH-deficiency history support a real human evidence base. Broad adult anti-aging outcomes remain unestablished.[14][30][3]

30%

Animal / preclinical

Limited

Preclinical and route-degradation work mainly supports pharmacology and formulation questions. It is not the main confidence driver for sermorelin.[29][1]

65%

Mechanism support

Moderate

GHRH(1-29) receptor activity provides a clear upstream GH-release mechanism when pituitary function is intact.[14][3]

Forms & administration

Sermorelin administration is route-specific. Modern compounded protocols usually use subcutaneous injection, while intranasal research is older and not directly interchangeable.[31][30][13]

InjectableNasal spray

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Injectable protocols use 0.2-0.5 mg per dose. Intranasal products use about 100 mcg per spray.[30][31]

Frequency

Injections are used once daily. Intranasal products are commonly used 5 nights per week.[30]

Timing Considerations

Before bed is the usual timing.[14]

Cycle Length

Injectable treatment periods run 3-6 months. Intranasal use may be ongoing.[4][24]

What to expect

Weeks 2-4

Bedtime injectable use may first show changes in sleep quality, morning energy, appetite, or water retention.[4]

Weeks 8-12

IGF-1, fasting glucose, waist, recovery notes, and training tolerance become clearer once bedtime timing is consistent.[24]

3-6 months

Longer cycles show whether GH-axis markers, waist, sleep, and recovery patterns remain aligned with the original goal.[4][30]

After stopping

Sleep, appetite, water retention, and IGF-1-related markers may drift toward baseline after GH-axis stimulation ends.[4][30]

Safety profile

Injectable sermorelin safety centers on injection-site tolerance, flushing or headache, water retention, glucose and IGF-1 effects, pregnancy avoidance, active malignancy caution, and sports prohibition.[31][30]

Common side effects

  • Injection-site pain or swelling[33]
  • Flushing[3]
  • Headache[3]
  • Water retention[24]

Cautions

Who Sermorelin is not for

Route-specific avoid and medical-review notes:

  • Active or recent cancer

    Avoid outside specialist-directed care because GH/IGF-1 pathway stimulation can be inappropriate in malignancy contexts.[31][30]

  • Pregnancy or breastfeeding

    Avoid because reproductive and lactation safety are not established for unapproved GH secretagogue use.[31][30]

  • Acromegaly or GH excess

    Do not add GH secretagogue stimulation when GH/IGF-1 excess is present or suspected.[31][30]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

  • Diabetes medications

    Diabetes medications can become harder to adjust when injectable GH-axis stimulation shifts glucose control; this is a theoretical GH/insulin-axis caution.[31][30]

  • Other GH-axis agents

    GHRH analogs, GHRPs, or HGH can add overlapping IGF-1, water-retention, glucose, and sports-risk concerns with injectable sermorelin; this is a stack-level safety caution.[31][30]

Pairing notes

Not recommended with

Somatropin: compounded GH/IGF-1 effectsInjectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[30][32][35]

Tesamorelin: overlapping GHRH signalingInjectable, Intranasal

Tesamorelin and sermorelin both activate GHRH-receptor signaling and increase endogenous growth-hormone release. Their different formulations do not establish a benefit from overlapping use.[36][30][32]

CJC-1295: overlapping GHRH signalingInjectable, Intranasal

Sermorelin and CJC-1295 both stimulate the GHRH receptor. CJC-1295 extends exposure, but overlapping the two still duplicates upstream GH/IGF-1 stimulation.[30][37][38]

CJC-1295 No DAC: overlapping GHRH signalingInjectable, Intranasal

Sermorelin and CJC-1295 No DAC are closely related GHRH-receptor approaches. Using both duplicates growth-hormone release signaling without a validated combined regimen.[30][39][32]

Related peptides

How it works

Sermorelin is GHRH(1-29), the N-terminal fragment that stimulates pituitary GHRH receptors. It acts through the GHRH pathway rather than the ghrelin/GHS receptor pathway used by GHRP-2, GHRP-6, or ipamorelin, so its food timing and stack logic are different.[14][3]

The mechanism requires responsive somatotroph cells, the GH-producing cells in the pituitary. That makes sermorelin a test or stimulation signal, not the same as exogenous GH replacement in severe pituitary failure. Route and formulation matter because short peptide degradation can limit exposure.[3][29][1]

Research gaps & open questions

What the current literature has not yet settled about Sermorelin:

01

Controlled trials in adults without diagnosed growth-hormone deficiency need to show whether Sermorelin meaningfully improves fat loss, lean mass, sleep, physical function, or wellbeing, and how it affects blood sugar and IGF-1.[4][24]

02

Studies need to show whether today's compounded Sermorelin products match historical Geref in identity, purity, release, and clinical effect.[31][33]

03

Research should identify how age, pituitary health, starting IGF-1, and the body's growth-hormone-braking signal affect who responds and who does not.[14]

Common questions

Is sermorelin currently FDA-approved?

No current marketed FDA-approved sermorelin option is listed. Geref was a discontinued sermorelin acetate product, and compounded versions are separate from FDA approval.[31][33]

How is sermorelin different from GHRPs?

Sermorelin is a GHRH fragment that stimulates pituitary GHRH receptors; GHRP-class peptides act through ghrelin/GHS receptor signaling.[14][3]

Is sermorelin banned in tested sports?

Yes. WADA treats GHRH analogs such as sermorelin as S2-prohibited without a valid TUE.[34]

Myths & misconceptions

Myth

Sermorelin is currently sold as an FDA-approved product.

Reality

The historical Geref product is listed as discontinued; compounded products are not the same as a currently marketed FDA-approved product.[31][33]

Myth

Sermorelin works just like injected HGH.

Reality

Sermorelin stimulates upstream pituitary release; it requires responsive pituitary cells and is not equivalent to exogenous GH replacement.[14]

History & discovery

Sermorelin's history sits between classic pediatric endocrinology and modern compounded GH-axis use: it is a GHRH(1-29) analog that once had a marketed FDA-approved product, Geref.[31][3]

Early studies used GRF(1-29) and somatomedin C/IGF-1 measurements to evaluate growth hormone deficiency and pituitary responsiveness.[14]

Once-daily subcutaneous GHRH therapy was studied in children with growth hormone deficiency, establishing the clinical context behind Geref.[30]

Current FDA records list Geref as discontinued and not withdrawn for safety or effectiveness, which separates historical approval from today's compounded-market use.[31]

Published research39 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Stay on track with your long-term goals.

Use PepFlow to record your Sermorelin protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00